Purpose
|
Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR.
|
Characteristics
|
Tradename: SPRYCEL Source of Compound: synthetic Target: Src inhibitor,Abl inhibitor,c-Kit inhibitor,EPHA antagonist Receptor: Src,Abl, Lck, Yes, Fyn,c-Kit, EPHA 2 Status: USP
|
Purification
|
All the products are sent with COA, HPLC and NMR inspection report to guarantee the quality.
|
Purity
|
95?%
|
Formula
|
C22H26ClN7O2S
|
Solubility
|
DMSO 98 mg/mL,Water <1 mg="" ml="" <="" td="">
1> |